2025-2031 Global Seasonal Influenza Vaccines Industry Research & Trends Analysis Report- YH Research

Home > Reports >Pharma & Healthcare > 2025-2031 Global Seasonal Influenza Vaccines Industry Research & Trends Analysis Report

2025-2031 Global Seasonal Influenza Vaccines Industry Research & Trends Analysis Report

Publication Date: 2025-12-12
Report Id: 2862878
Industry: Pharma & Healthcare
Report Page: 137
Chart: 134

PDF Download

Publication Date: 2025-12-12
Report Id: 2862878
Industry: Pharma & Healthcare
Report Page: 137
Chart: 134

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Seasonal Influenza Vaccines Definition
1.2 Global Seasonal Influenza Vaccines Market Size and Forecast
1.2.1 By Revenue, Global Seasonal Influenza Vaccines Market Size, 2020-2031
1.2.2 By Sales Volume, Global Seasonal Influenza Vaccines Market Size, 2020-2031
1.2.3 Global Seasonal Influenza Vaccines Price Trend, 2020-2031
1.3 China Seasonal Influenza Vaccines Market Size and Forecast
1.3.1 By Revenue, China Seasonal Influenza Vaccines Market Size, 2020-2031
1.3.2 By Sales Volume, China Seasonal Influenza Vaccines Market Size, 2020-2031
1.3.3 China Seasonal Influenza Vaccines Price Trend, 2020-2031
1.4 China Percentage in Global Market
1.4.1 By Revenue, China Seasonal Influenza Vaccines Share in Global Market, 2020-2031
1.4.2 By Sales Volume, China Seasonal Influenza Vaccines Share in Global Market, 2020-2031
1.4.3 Seasonal Influenza Vaccines Market Size: China VS Global, 2020-2031
1.5 Seasonal Influenza Vaccines Market Dynamics
1.5.1 Seasonal Influenza Vaccines Market Drivers
1.5.2 Seasonal Influenza Vaccines Market Restraints
1.5.3 Seasonal Influenza Vaccines Industry Trends
1.5.4 Seasonal Influenza Vaccines Industry Policy

2 Global Competitive Landscape by Company
2.1 Global Seasonal Influenza Vaccines Revenue by Company, 2020-2025
2.2 Global Seasonal Influenza Vaccines Sales Volume by Company, 2020-2025
2.3 Global Seasonal Influenza Vaccines Price by Company, 2020-2025
2.4 Global Seasonal Influenza Vaccines Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global Seasonal Influenza Vaccines Concentration Ratio
2.6 Global Seasonal Influenza Vaccines Mergers & Acquisitions, Expansion Plans
2.7 Global Seasonal Influenza Vaccines Manufacturers Product Type

3 China Competitive Landscape by Company
3.1 China Seasonal Influenza Vaccines Revenue by Company, 2020-2025
3.2 China Seasonal Influenza Vaccines Sales Volume by Company, 2020-2025
3.3 China Seasonal Influenza Vaccines Seasonal Influenza Vaccines Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.4 China Seasonal Influenza Vaccines Market, Sales Percentage of Local Players VS Foreign Players (2020-2025)
3.5 Chinese Local Players, Seasonal Influenza Vaccines Domestic VS Export
3.6 China Market, Seasonal Influenza Vaccines Import & Export
3.6.1 China Market, Seasonal Influenza Vaccines Import & Export, 2020-2031
3.6.2 China Seasonal Influenza Vaccines Import & Export Trends
3.6.3 Main Sources of China Seasonal Influenza Vaccines Import
3.6.4 Export Destination of China Seasonal Influenza Vaccines

4 Seasonal Influenza Vaccines Production by Region
4.1 Global Seasonal Influenza Vaccines Capacity, Production and Capacity Utilization, 2020-2031
4.2 Global Geographic Distribution of Seasonal Influenza Vaccines Manufacturers
4.3 Global Major Manufacturers, Seasonal Influenza Vaccines Capacity Expansion and Future Plans
4.4 Global Seasonal Influenza Vaccines Capacity by Region
4.5 Global Seasonal Influenza Vaccines Production by Region
4.5.1 Global Seasonal Influenza Vaccines Production & Forecast by Region, 2020 VS 2024 VS 2031
4.5.2 Global Seasonal Influenza Vaccines Production by Region, 2020-2025
4.5.3 Global Seasonal Influenza Vaccines Production Market Share & Forecast by Region, 2020-2031

5 Industry Chain Analysis
5.1 Seasonal Influenza Vaccines Industry Chain
5.2 Seasonal Influenza Vaccines Upstream Analysis
5.2.1 Seasonal Influenza Vaccines Core Raw Materials
5.2.2 Main Manufacturers of Seasonal Influenza Vaccines Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 Seasonal Influenza Vaccines Production Mode
5.6 Seasonal Influenza Vaccines Procurement Model
5.7 Seasonal Influenza Vaccines Industry Sales Model and Sales Channels
5.7.1 Seasonal Influenza Vaccines Sales Model
5.7.2 Seasonal Influenza Vaccines Typical Distributors

6 Sights by Type
6.1 Seasonal Influenza Vaccines Classification by Type
6.1.1 Trivalent Influenza Vaccine
6.1.2 Quadrivalent Influenza Vaccine
6.2 by Type, Global Seasonal Influenza Vaccines Market Size & CAGR, 2020 VS 2024 VS 2031
6.3 by Type, Global Seasonal Influenza Vaccines Revenue, 2020-2031
6.4 by Type, Global Seasonal Influenza Vaccines Sales Volume, 2020-2031
6.5 by Type, Global Seasonal Influenza Vaccines Price, 2020-2031

7 Sights by Technology
7.1 Seasonal Influenza Vaccines Classification by Technology
7.1.1 Chicken Embryo Technology
7.1.2 Cell Culture Technology
7.1.3 Recombinant Technology
7.1.4 Adjuvant Vaccines
7.2 by Technology, Global Seasonal Influenza Vaccines Market Size & CAGR, 2020 VS 2024 VS 2031
7.3 by Technology, Global Seasonal Influenza Vaccines Revenue, 2020-2031
7.4 by Technology, Global Seasonal Influenza Vaccines Sales Volume, 2020-2031
7.5 by Technology, Global Seasonal Influenza Vaccines Price, 2020-2031

8 Sights by Administration
8.1 Seasonal Influenza Vaccines Classification by Administration
8.1.1 Injectable
8.1.2 Nasal Spray
8.2 by Administration, Global Seasonal Influenza Vaccines Market Size & CAGR, 2020 VS 2024 VS 2031
8.3 by Administration, Global Seasonal Influenza Vaccines Revenue, 2020-2031
8.4 by Administration, Global Seasonal Influenza Vaccines Sales Volume, 2020-2031
8.5 by Administration, Global Seasonal Influenza Vaccines Price, 2020-2031

9 Sights by Application
9.1 Seasonal Influenza Vaccines Segment by Application
9.1.1 6 Months to 3 Years
9.1.2 > 3 Years
9.2 by Application, Global Seasonal Influenza Vaccines Market Size & CAGR, 2020 VS 2024 VS 2031
9.3 by Application, Global Seasonal Influenza Vaccines Revenue, 2020-2031
9.4 by Application, Global Seasonal Influenza Vaccines Sales Volume, 2020-2031
9.5 by Application, Global Seasonal Influenza Vaccines Price, 2020-2031

10 Sales Sights by Region
10.1 By Region, Global Seasonal Influenza Vaccines Market Size, 2020 VS 2024 VS 2031
10.2 By Region, Global Seasonal Influenza Vaccines Revenue, 2020-2031
10.3 By Region, Global Seasonal Influenza Vaccines Sales Volume, 2020-2031
10.4 North America
10.4.1 North America Seasonal Influenza Vaccines Market Size & Forecasts, 2020-2031
10.4.2 By Country, North America Seasonal Influenza Vaccines Market Size Market Share
10.5 Europe
10.5.1 Europe Seasonal Influenza Vaccines Market Size & Forecasts, 2020-2031
10.5.2 By Country, Europe Seasonal Influenza Vaccines Market Size Market Share
10.6 Asia Pacific
10.6.1 Asia Pacific Seasonal Influenza Vaccines Market Size & Forecasts, 2020-2031
10.6.2 By Country/Region, Asia Pacific Seasonal Influenza Vaccines Market Size Market Share
10.7 South America
10.7.1 South AmericaSeasonal Influenza Vaccines Market Size & Forecasts, 2020-2031
10.7.2 By Country, South America Seasonal Influenza Vaccines Market Size Market Share
10.8 Middle East & Africa

11 Sales Sights by Country Level
11.1 By Country, Global Seasonal Influenza Vaccines Market Size & CAGR，2020 VS 2024 VS 2031
11.2 By Country, Global Seasonal Influenza Vaccines Revenue, 2020-2031
11.3 By Country, Global Seasonal Influenza Vaccines Sales Volume, 2020-2031
11.4 United States
11.4.1 United States Seasonal Influenza Vaccines Market Size, 2020-2031
11.4.2 By Company, United States Seasonal Influenza Vaccines Sales Volume Market Share, 2024
11.4.3 by Type, United States Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.4.4 by Application, United States Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.5 Europe
11.5.1 Europe Seasonal Influenza Vaccines Market Size, 2020-2031
11.5.2 By Company, Europe Seasonal Influenza Vaccines Sales Volume Market Share, 2024
11.5.3 by Type, Europe Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.5.4 by Application, Europe Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.6 China
11.6.1 China Seasonal Influenza Vaccines Market Size, 2020-2031
11.6.2 By Company, China Seasonal Influenza Vaccines Sales Volume Market Share, 2024
11.6.3 by Type, China Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.6.4 by Application, China Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.7 Japan
11.7.1 Japan Seasonal Influenza Vaccines Market Size, 2020-2031
11.7.2 By Company, Japan Seasonal Influenza Vaccines Market Share, 2024
11.7.3 by Type, Japan Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.7.4 by Application, Japan Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.8 South Korea
11.8.1 South Korea Seasonal Influenza Vaccines Market Size, 2020-2031
11.8.2 By Company, South Korea Seasonal Influenza Vaccines Market Share, 2024
11.8.3 by Type, South Korea Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.8.4 by Application, South Korea Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.9 Southeast Asia
11.9.1 Southeast Asia Seasonal Influenza Vaccines Market Size, 2020-2031
11.9.2 By Company, Southeast Asia Seasonal Influenza Vaccines Market Share, 2024
11.9.3 by Type, Southeast Asia Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.9.4 by Application, Southeast Asia Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.10 India
11.10.1 India Seasonal Influenza Vaccines Market Size, 2020-2031
11.10.2 By Company, India Seasonal Influenza Vaccines Market Share, 2024
11.10.3 by Type, India Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.10.4 by Application, India Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.11 Middle East & Africa
11.11.1 Middle East & Africa Seasonal Influenza Vaccines Market Size, 2020-2031
11.11.2 By Company, Middle East & Africa Seasonal Influenza Vaccines Market Share, 2024
11.11.3 by Type, Middle East & Africa Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031
11.11.4 by Application, Middle East & Africa Seasonal Influenza Vaccines Market Size, Share, 2024 VS 2031

12 Manufacturers Profile
12.1 Sanofi
12.1.1 Sanofi Company Information, Head Office, Market Area, and Industry Position
12.1.2 Sanofi Seasonal Influenza Vaccines Models, Specifications, and Application
12.1.3 Sanofi Seasonal Influenza Vaccines Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.1.4 Sanofi Company Profile and Main Business
12.1.5 Sanofi Recent Developments
12.2 CSL
12.2.1 CSL Company Information, Head Office, Market Area, and Industry Position
12.2.2 CSL Seasonal Influenza Vaccines Models, Specifications, and Application
12.2.3 CSL Seasonal Influenza Vaccines Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.2.4 CSL Company Profile and Main Business
12.2.5 CSL Recent Developments
12.3 GSK
12.3.1 GSK Company Information, Head Office, Market Area, and Industry Position
12.3.2 GSK Seasonal Influenza Vaccines Models, Specifications, and Application
12.3.3 GSK Seasonal Influenza Vaccines Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.3.4 GSK Company Profile and Main Business
12.3.5 GSK Recent Developments
12.4 Viatris
12.4.1 Viatris Company Information, Head Office, Market Area, and Industry Position
12.4.2 Viatris Seasonal Influenza Vaccines Models, Specifications, and Application
12.4.3 Viatris Seasonal Influenza Vaccines Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.4.4 Viatris Company Profile and Main Business
12.4.5 Viatris Recent Developments
12.5 AstraZeneca
12.5.1 AstraZeneca Company Information, Head Office, Market Area, and Industry Position
12.5.2 AstraZeneca Seasonal Influenza Vaccines Models, Specifications, and Application
12.5.3 AstraZeneca Seasonal Influenza Vaccines Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.5.4 AstraZeneca Company Profile and Main Business
12.5.5 AstraZeneca Recent Developments
12.6 Hualan Bio
12.6.1 Hualan Bio Company Information, Head Office, Market Area, and Industry Position
12.6.2 Hualan Bio Seasonal Influenza Vaccines Models, Specifications, and Application
12.6.3 Hualan Bio Seasonal Influenza Vaccines Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.6.4 Hualan Bio Company Profile and Main Business
12.6.5 Hualan Bio Recent Developments
12.7 Changchun Institute of Biological
12.7.1 Changchun Institute of Biological Company Information, Head Office, Market Area, and Industry Position
12.7.2 Changchun Institute of Biological Seasonal Influenza Vaccines Models, Specifications, and Application
12.7.3 Changchun Institute of Biological Seasonal Influenza Vaccines Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.7.4 Changchun Institute of Biological Company Profile and Main Business
12.7.5 Changchun Institute of Biological Recent Developments
12.8 Sinovac
12.8.1 Sinovac Company Information, Head Office, Market Area, and Industry Position
12.8.2 Sinovac Seasonal Influenza Vaccines Models, Specifications, and Application
12.8.3 Sinovac Seasonal Influenza Vaccines Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.8.4 Sinovac Company Profile and Main Business
12.8.5 Sinovac Recent Developments
12.9 BCHT
12.9.1 BCHT Company Information, Head Office, Market Area, and Industry Position
12.9.2 BCHT Seasonal Influenza Vaccines Models, Specifications, and Application
12.9.3 BCHT Seasonal Influenza Vaccines Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.9.4 BCHT Company Profile and Main Business
12.9.5 BCHT Recent Developments
12.10 Jiangsu GDK
12.10.1 Jiangsu GDK Company Information, Head Office, Market Area, and Industry Position
12.10.2 Jiangsu GDK Seasonal Influenza Vaccines Models, Specifications, and Application
12.10.3 Jiangsu GDK Seasonal Influenza Vaccines Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.10.4 Jiangsu GDK Company Profile and Main Business
12.10.5 Jiangsu GDK Recent Developments
12.11 KM Biologics
12.11.1 KM Biologics Company Information, Head Office, Market Area, and Industry Position
12.11.2 KM Biologics Seasonal Influenza Vaccines Models, Specifications, and Application
12.11.3 KM Biologics Seasonal Influenza Vaccines Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.11.4 KM Biologics Company Profile and Main Business
12.11.5 KM Biologics Recent Developments

13 Conclusion

14 Appendix
14.1 Research Methodology
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Market Estimation Model
14.4 Disclaimer

According to YH Research, the global market for Seasonal Influenza Vaccines should grow from US$ 9713 million in 2024 to US$ 14080 million by 2031, with a CAGR of 5.2% for the period of 2025-2031.

The strategic recalibration of 2025 U.S. tariff mechanisms is redefining global economic governance norms. This study deciphers the transmission mechanisms of tariff escalation pathways and global policy responses on corporate investment strategies, regional trade networks, and critical material supply architectures.

Seasonal Influenza Vaccines

According to YH Research, the global market for Seasonal Influenza Vaccines should grow from US$ 9713 million in 2024 to US$ 14080 million by 2031, with a CAGR of 5.2% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

Seasonal Influenza Vaccines are prophylactic biological products formulated each season to target influenza A and B strains that are circulating or predicted to circulate. By delivering specific viral surface antigens or genetic instructions encoding these antigens (through protein subunits, recombinant platforms, or mRNA), these vaccines stimulate neutralizing antibodies and cellular immunity to reduce infection, severe disease, and complications. Contemporary seasonal influenza vaccines span multiple technology platforms — traditional egg-based/inactivated formulations, cell-based production, recombinant protein technologies, and the emergent mRNA platform. Given antigenic drift of influenza viruses, annual public-health prioritization, and shifting government immunization programs, seasonal influenza vaccines serve both as a public-health staple and a strategic, value-generating product category for vaccine firms pursuing technological upgrades, capacity coordination, and public-sector partnerships.In 2024,   global In 2024,   global Flu (Influenza) Vaccine production reached approximately 845.8 m units, with an average global market   price of around US$ 10.8 perunit.The average gross profit margin of this product is 56%. production reached approximately 845.8 m units, with an average global market   price of around US$ 10.8 perunit.The average gross profit margin of this product is 56%.

Against a background of strengthened public-health systems and rapid vaccine-technology advances, the seasonal influenza vaccine market faces structural growth opportunities. Governments are continuously improving annual influenza protection strategies, expanding priority-group coverage, and enhancing surveillance systems—providing policy-backed demand. Technological progress—especially the commercialization of cell-based platforms, recombinant protein approaches and mRNA technology—improves antigen matching, production control and speed of response to emerging strains, reshaping product portfolios and supply capabilities. Leading companies’ epidemiology and impact reports repeatedly highlight the direct benefits of increased vaccination in reducing hospitalizations and healthcare strain; from a corporate perspective, strengthening technological capabilities and supply reliability unlocks opportunities in both public procurement and private markets.

Growth is constrained by rising regulatory expectations, the inherent uncertainty of annual strain selection, and the capital- and compliance-intensive nature of large-scale production. Regulators are increasing requirements for batch consistency, demonstrated protection, and rapid traceability, pushing up R&D and quality-system costs. Egg-based production still dominates in several regions, exposing upstream supply chains to seasonal and regional vulnerabilities for eggs, media and critical reagents. Industry consolidation further raises barriers to entry, making negotiation power and channel access more difficult for smaller players. Corporate annual reports underscore that weaknesses in any corner of the “capital–compliance–capacity” triangle can amplify commercial risk.

Downstream demand shows a dual pattern of “normalization plus premiumization”: aging populations, rising chronic-disease prevalence and improved public awareness are shifting vaccination from event-driven to routine protection. Buyers increasingly demand differentiated products (e.g., formulations optimized for vulnerable populations or enhanced breadth) and guaranties of supply stability, steering the market toward “functional products + contracted supply.” Government procurement, insurance coverage and corporate vaccination programs are key drivers of coverage; digital booking systems, expanded primary-care networks and large-scale institutional partnerships provide scalable distribution channels and brand-building opportunities. Overall, downstream is evolving from pure volume replacement toward long-term cooperation emphasizing quality, delivery and services. 
Upstream inputs include seed strains and reference reagents, culture media and cell lines or eggs, single-use process kits, purification resins and QC assay reagents. As the industry shifts toward cell-based and genetic-engineering platforms, demand for high-reliability, batch-consistent, GMP-grade single-use materials has grown significantly; localization and multi-sourcing of critical inputs are strategic priorities to mitigate supply-chain disruption risk. Company reports show that strategic long-term partnerships between manufacturers and material suppliers, vertical integration of production capacity, and OEM/CMO models are important levers to secure annual supply and respond to emergent strain challenges. In short, upstream robustness underpins firms’ annual delivery capability and market credibility.

This report aims to provide a comprehensive study of the global market for Seasonal Influenza Vaccines. 
Report Highlights:
(1) Global Seasonal Influenza Vaccines market size (sales volume & revenue), history data from 2020-2025, and forecast data from 2026 to 2031.

(2) Global Seasonal Influenza Vaccines market competitive situation, sales, revenue, price, and market share, from 2020 to 2025.

(3) China Seasonal Influenza Vaccines market competitive situation, sales, revenue, price, and market share, from 2020 to 2025.

(4) Global Seasonal Influenza Vaccines segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global Seasonal Influenza Vaccines segment by Type, and by Application, and regional segment by Type, and by Application.

(6) Global major production regions of Seasonal Influenza Vaccines, capacity, production and trends.

(7) Seasonal Influenza Vaccines industry supply chain, upstream, midstream, and downstream analysis.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Type, covers
    Trivalent Influenza Vaccine
    Quadrivalent Influenza Vaccine

Market segment by Technology, covers
    Chicken Embryo Technology
    Cell Culture Technology
    Recombinant Technology
    Adjuvant Vaccines

Market segment by Administration, covers
    Injectable
    Nasal Spray

Market segment by Application, can be divided into
    6 Months to 3 Years
    > 3 Years

Market segment by players, this report covers
    Sanofi
    CSL
    GSK
    Viatris
    AstraZeneca
    Hualan Bio
    Changchun Institute of Biological
    Sinovac
    BCHT
    Jiangsu GDK
    KM Biologics